Latest news with #JohnHester
Business Insider
3 days ago
- Business
- Business Insider
Bell Potter Remains a Buy on Clarity Pharmaceuticals Ltd. (CU6)
Bell Potter analyst John Hester maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) today and set a price target of A$4.90. The company's shares opened today at A$2.18. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Mesoblast Limited, and Telix Pharmaceuticals. According to TipRanks, Hester has an average return of 4.3% and a 46.74% success rate on recommended stocks. Clarity Pharmaceuticals Ltd. has an analyst consensus of Strong Buy, with a price target consensus of A$6.15, a 182.11% upside from current levels. In a report released on June 15, Wilsons also maintained a Buy rating on the stock with a A$8.25 price target.
Business Insider
12-06-2025
- Business
- Business Insider
Bell Potter Remains a Buy on Radiopharm Theranostics Limited (RAD)
Bell Potter analyst John Hester maintained a Buy rating on Radiopharm Theranostics Limited (RAD – Research Report) today and set a price target of A$0.05. The company's shares closed today at A$0.03. Confident Investing Starts Here: According to TipRanks, Hester is a 4-star analyst with an average return of 7.3% and a 50.55% success rate. Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Polynovo , and Mesoblast Limited. Currently, the analyst consensus on Radiopharm Theranostics Limited is a Moderate Buy with an average price target of A$0.05. The company has a one-year high of A$0.05 and a one-year low of A$0.02. Currently, Radiopharm Theranostics Limited has an average volume of 4.33M. Based on the recent corporate insider activity of 12 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of RAD in relation to earlier this year.
Business Insider
11-06-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for Clarity Pharmaceuticals Ltd. (CU6)
Bell Potter analyst John Hester maintained a Buy rating on Clarity Pharmaceuticals Ltd. (CU6 – Research Report) today and set a price target of A$4.90. The company's shares closed today at A$2.39. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.2% and a 50.00% success rate. Hester covers the Healthcare sector, focusing on stocks such as Clarity Pharmaceuticals Ltd., Polynovo , and Mesoblast Limited. Currently, the analyst consensus on Clarity Pharmaceuticals Ltd. is a Strong Buy with an average price target of A$6.22, representing a 160.25% upside. In a report released on June 5, Canaccord Genuity also maintained a Buy rating on the stock with a A$6.74 price target.
Business Insider
05-06-2025
- Business
- Business Insider
Bell Potter Reaffirms Their Buy Rating on Cyclopharm Limited (CYC)
In a report released today, John Hester from Bell Potter maintained a Buy rating on Cyclopharm Limited (CYC – Research Report), with a price target of A$2.20. The company's shares closed today at A$1.14. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.1% and a 50.56% success rate. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. The word on The Street in general, suggests a Hold analyst consensus rating for Cyclopharm Limited. The company has a one-year high of A$2.50 and a one-year low of A$1.03. Currently, Cyclopharm Limited has an average volume of 92.52K.
Business Insider
29-05-2025
- Business
- Business Insider
Bell Potter Sticks to Their Buy Rating for Radiopharm Theranostics Limited (RAD)
In a report released today, John Hester from Bell Potter maintained a Buy rating on Radiopharm Theranostics Limited (RAD – Research Report), with a price target of A$0.05. The company's shares closed today at A$0.03. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Hester is a 4-star analyst with an average return of 7.4% and a 50.57% success rate. Hester covers the Healthcare sector, focusing on stocks such as Polynovo , Mesoblast Limited, and Telix Pharmaceuticals. The analyst consensus on Radiopharm Theranostics Limited is currently a Hold rating.
